DRUG · Bright Minds Biosciences Inc.

Summary

Bright Minds Biosciences Inc. reported a net loss of $7,565,318 for the three months ended December 31, 2025, compared to net income of $49,610 for the same period in 2024, primarily due to increased research and development expenses. The company disclosed its condensed interim financial statements and management discussion, highlighting its clinical-stage pipeline and reliance on equity financings to fund operations.

Key takeaways

• Reported a net loss of $7,565,318 for Q1 ended December 31, 2025, compared to net income of $49,610 in the prior year period.
• Research and development expenses increased to $5,660,654 from $1,045,368 year-over-year.
• Cash and cash equivalents were $89,047,867 as of December 31, 2025, up from $82,908,589 at September 30, 2025.
• The company is a clinical-stage biotechnology company developing BMB-101 for drug-resistant epilepsies, with Phase 2 BREAKTHROUGH study showing positive topline results.
• Management stated the company is not able to finance day-to-day activities through operations and intends to fund operations with equity financings and loans from directors.